Medtech - An attractive market for private equity

tenormin buy Attractive business model coupled with market liquidity are driving up premiums however significant care should be taken on finding the right asset

Read more

Body countouring - The next botox?

Following Allergan's announcement on 13 February of its acquisition of bodycountouring specialist ZELTIQ for $2.7bn...

Read more

The future of UK pharmacies

UK pharmacy valuations have been on the rise driven by significantly more demand than supply for pharmacy acquisitions. The UK…

Read more


  • Trevena goes for MOR than morphine October 13, 2018
    A split panel on Trevena’s pain candidate oliceridine likely won’t do much to turn FDA’s skepticism, but leaves a chance for the company to bolster its case with more data.
  • COI failure fallout October 13, 2018
    Jose Baselga’s resignation as CMO at MSKCC exposes the byzantine inconsistencies around how researchers are expected to handle COI.
  • Bourla’s breadcrumbs to value October 13, 2018
    Changes made during his short stint on Pfizer’s innovation drugs side signal that incoming CEO Albert Bourla could reshape the pharma’s drug pricing strategy.
  • Versant seizes the RNA moment October 12, 2018
    Versant seeded and launched RNA epigenetics company Gotham with $54M as the RNA space continues to heat up.
  • Earnings on deck October 12, 2018
  • Targeting GPCRs, Ab Initio October 12, 2018
    How Ab Initio is leveraging its biochemistry know-how to make mAbs that modulate GPCRs.
  • Spinning out Sitryx October 12, 2018
    With a $30 million series A and a full pipeline, Sitryx became the first company to emerge from GSK’s Immunology Network.
  • A Glympse at drug response October 12, 2018
    Glympse is applying its sensors to diagnostics and drug response monitoring and raised $22M to bring its NASH sensor to the clinic.
  • SUPPORTing FDA’s fight against opioids abuse October 6, 2018
    The SUPPORT Act will give FDA new powers to combat opioid abuse and addiction, and will help medicalize addiction treatment.
  • In sight of uncharted territory October 6, 2018
    While some buysiders see red flags as biotech indexes approach all-time highs, most investors say macro risks are more cause for worry than a correction based on valuations.